MS treatment developer Mapi Pharma raises $10m

Dr. Ehud Marom
Dr. Ehud Marom

Mapi Pharma is close to beginning Phase III trials for once-a-month Copaxone.

Mapi Pharma, which is developing a version of multiple sclerosis drug Copaxone, has raised $10 million. Mapi's version of the drug is administered once a month, compared with the delayed release version by Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), which is administered several times a week. Shavit Capital Fund led the round, with participation from Mapi chairman and CEO Ehud Marom, who invested his own money.

Founded by Marom, who formerly worked on Teva's Copaxone team, Mapi attempted a Nasdaq IPO twice in 2014, first seeking to raise $40 million at a company value of $200-230 million, and then submitting a more modest prospectus for raising $20 million as a company value of $120 million. Neither offering was successful, but the company said in the past that it was not giving up, and would again try to raise $10-30 million. The company's announcement today did not say whether it would embark on an IPO, but the fact that the current round was led by Shavit Capital, whose business model is to invest in companies that are candidates for stock exchange offerings, makes such move likely.

Marom said, "The financing round is designed to enable the company to complete its Phase II trial (testing initial effectiveness and safety) of its product, for which we have already recruited 12 patients, with positive results so far for both safety and effectiveness, and to begin a Phase III trial. We have met with the FDA (US Food and Drug Administration), which authorized us to begin a Phase III trial in the first quarter of 2016, even if we have not completed the Phase II trials by then. The FDA also authorized us to submit the product for registration on the basis of a single Phase III trial on 920 patients, without any additional trials."

If everything goes according to plan, Marom believes that the product will reach the market in 2019.

According to Marom, this development with the FDA and the initial results of the Phase II trial is only one of the areas in which the company made progress over the past year, making a Nasdaq IPO not worthwhile at a lower value. He believes that this progress will enable the company to hold a large offering later, whether on Nasdaq or through another instrument. He also cited the good performance of Teva's Copaxone, the original drug, against competition from new products, as another positive factor. "I know Copaxone very well, and I believe that it is an excellent product. We only want to offer an upgrade of it," he says. Mapi is currently producing the raw material - in effect generic Copaxone - for its product by itself. Once a Phase III trials begins, the possibility of cooperation with another company producing generic Copaxone, and even with Teva itself, will be considered.

Another development concerns the Company's other products, which are administered through delayed release, and therefore in a monthly dosage. Since the company called off its IPO, joint drug development and marketing agreements have been signed with major pharmaceutical companies. Mapi is not disclosing with which companies the agreements have been signed, but Marom says that one of the products is a drug for Aids. "Thanks to these agreements, we are likely to see initial revenue already in 2017." Know-how agreements has also been signed for Mapi's method of administering certain products, and with several Chinese pharmaceutical companies for marketing exclusively in the Chinese market. "But these aren't our main products. The flagship product is GA Depot - once-a-month Copaxone."

Published by Globes [online], Israel business news - www.globes-online.com - on May 27, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

Dr. Ehud Marom
Dr. Ehud Marom
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018